Outlook Therapeutics, Inc. (OTLK) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, Outlook Therapeutics reported revenue of $1.4M. Net income was -$62.4M (a -4416.2% net margin), or -$1.79 per diluted share. Gross margin was 4.0% and operating margin was -4744.3%. Operating activities generated -$51.8M of cash. At fiscal year end, Outlook Therapeutics held $18.6M in total assets against $50.8M in total liabilities, including $8.1M of cash and equivalents.
Open the full interactive Outlook Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Outlook Therapeutics Key Stats
| Share Price | $0.56 |
|---|---|
| Market Cap | $77.1M |
| 52-Week Range | $0.20 – $2.47 |
| Shares Outstanding | 136.7 million (basic, 2026 Q3) |
Outlook Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $1.4M |
| Cost of Goods Sold | — | — | — | — | — | $1.4M |
| Gross Profit | — | — | — | — | — | $57,205 |
| Operating Income | -$36.8M | -$51.7M | -$63.1M | -$53.1M | -$71.7M | -$67.1M |
| Pre-Tax Income | -$38.5M | -$53.2M | -$66.0M | -$59.0M | -$75.4M | -$64.0M |
| Income Tax | -$3.3M | $2,000 | $2,800 | $2,800 | $2,800 | -$1.6M |
| Net Income | -$35.2M | -$53.2M | -$66.1M | -$59.0M | -$75.4M | -$62.4M |
| Diluted EPS | -$13.40 | -$7.00 | -$6.20 | -$4.80 | -$4.06 | -$1.79 |
Outlook Therapeutics Quarterly Results
| 2025 Q4 | 2026 Q1 | 2026 Q2 | 2026 Q3 | |
|---|---|---|---|---|
| Revenue | — | -$1.2M | $127,439 | $8,700 |
| Net Income | -$13.3M | -$23.1M | -$4.5M | -$20.3M |
| Diluted EPS | -$0.38 | -$0.38 | -$0.05 | -$0.15 |
Outlook Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $12.5M | $14.5M | $17.4M | $23.4M | $14.9M | $8.1M |
| Current Assets | $17.9M | $21.5M | $27.5M | $31.0M | $27.4M | $17.4M |
| Total Assets | $19.7M | $22.8M | $28.5M | $32.3M | $28.8M | $18.6M |
| Current Liabilities | $15.9M | $6.8M | $19.7M | $46.7M | $42.6M | $45.8M |
| Total Long-Term Debt | $954,485 | $11.8M | $10.9M | $35.6M | — | — |
| Total Liabilities | $16.9M | $18.2M | $19.8M | $46.7M | $101.9M | $50.8M |
| Shareholders' Equity | $2.8M | $4.6M | $8.7M | -$14.4M | -$73.1M | -$32.2M |
Outlook Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$31.8M | -$54.3M | -$56.7M | -$43.0M | -$68.8M | -$51.8M |
| Cash From Investing | -$900,000 | — | — | — | — | — |
| Cash From Financing | $37.2M | $56.2M | $59.6M | $49.0M | $60.3M | $45.0M |
| Free Cash Flow | -$32.2M | — | — | — | — | — |
Figures from Outlook Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Outlook Therapeutics financials page for every line item.
Outlook Therapeutics Company Profile
| Ticker | OTLK |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | Iselin, New Jersey |
| Incorporated in | Delaware |
| Fiscal Year End | September 30 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001649989 |
Frequently Asked Questions
What was Outlook Therapeutics' revenue in fiscal 2025?
Outlook Therapeutics (OTLK) reported revenue of $1.4M for fiscal 2025.
What is Outlook Therapeutics' annual revenue history?
Outlook Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $1.4M.
What was Outlook Therapeutics' net income in fiscal 2025?
Outlook Therapeutics reported net income of -$62.4M for fiscal 2025.
What was Outlook Therapeutics' earnings per share (EPS) in fiscal 2025?
Outlook Therapeutics' diluted EPS was -$1.79 for fiscal 2025 (adjusted for any later stock splits).
What was Outlook Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q3), Outlook Therapeutics reported revenue of $8,700.
How many shares of Outlook Therapeutics are outstanding?
Outlook Therapeutics reported a weighted average of 136.7 million basic shares outstanding in 2026 Q3.
What is Outlook Therapeutics' market cap?
Based on its latest closing price, Outlook Therapeutics (OTLK) has a market capitalization of about $77.1M.
When does Outlook Therapeutics' fiscal year end?
Outlook Therapeutics' fiscal year end, as registered with the SEC, is September 30.
Where is Outlook Therapeutics headquartered?
Outlook Therapeutics lists its business address in Iselin, New Jersey in its SEC filings.
Outlook Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →